Camlin Fine Sciences Approves Audited FY26 Results; Appoints New CFO
Camlin Fine Sciences approved audited consolidated and standalone financial results for the year and quarter ended March 31, 2026. The 33rd AGM is scheduled for August 11, 2026. Mr. Pankaj Pandey will join as CFO on August 18, 2026, with Mr. Santosh Parab re-designated.
The appointment of a new CFO and re-designation of a key executive are significant management changes that can impact the company's strategic direction and operations. The approval of audited financial results is also material information for investors.
The announcement details the approval of financial results and several management appointments, which are routine corporate actions. While the financial results themselves may have a sentiment, the announcement of their approval and the appointments are neutral.
Camlin Fine Sciences Limited announced the outcome of its Board Meeting held on May 26, 2026. The Board approved the Audited Financial Statements (Consolidated and Standalone) for the year ended March 31, 2026, and the Audited Financial Results for the quarter and year ended March 31, 2026. The statutory auditors, M/s. Kalyaniwalla & Mistry LLP, issued unmodified opinions on these financial statements.
The company also announced that its 33rd Annual General Meeting (AGM) will be held on Tuesday, August 11, 2026, at 10:00 a.m.
In terms of management changes, the Board approved the appointment of Mr. Pankaj Pandey as Chief Financial Officer (CFO) and Key Managerial Personnel, effective August 18, 2026. Upon Mr. Pandey's joining, Mr. Santosh Parab will be re-designated as President – Strategy and Global CFO, also effective August 18, 2026.
Additionally, the Board approved the appointment of M/s. ABK & Associates as Cost Auditors and M/s. Mahajan & Aibara as Internal Auditors for the financial year ending March 31, 2027.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.